Popular Articles

A Yeast Cancer Model For Mapping Cancer Genes
Researchers have devised a scheme for identifying genes in yeast that
generic viagra online
Urologic Nurses To Discover Latest Clinical Practice Advances At Annual Conference
A specialty as diverse as urologic nursing requires comprehensive educational offerings that keep nurses up to date in the varied practice areas. The Society of Urologic Nurses and Associates (SUNA) will continue to show its commitment to excellence in clinical practice by hosting its 40th Annual Conference, October 2-5, 2009, at the Hyatt Regency Chicago, in Chicago, IL.
News of the day
Kaiser Daily Health Policy Report Feature Highlights Recent Blog Entries
"Blog Watch" offers readers a roundup of health policy-related blog posts.Appropriately, the last of the Senate Finance Committee"s three major public roundtables on health reform issues was on finance. Keith Hennessy lauds economist Kate Baicker"s testimony (.pdf) and says it helps connect reform ideas to a system of third-party payment. Hennessy says the current system leads people to "spend more of other people"s money than they do of their own, and less wisely." Hennessy explores the example of employer-sponsored insurance, which he says makes health insurance appear less expensive to employees than it is.Meanwhile, the New Republic"s Jonathan Cohn, who has been calling attention to potential ways of financing the significant cost of reform, recommends the testimony of Center on Budget and Policy Priorities President Robert Greenstein. Greenstein testified that there are no "painless" ways of raising money for reform, and said, "This leads to my first recommendation, in the form of a plea to the Committee. Please do not take any offset options off the table at this time. I believe you ultimately will need to put together a package that contains an array of spending and revenue offsets." Offsets could include removing or limiting the tax exclusion for employer-sponsored insurance. Bob Lazsewski strenuously disagrees. He illustrates a post titled "Paying for a Big Part of Health Care Reform With New Taxes Would Be a Terrible Mistake!" with a graph of the trends in health insurance premiums over the last 20 years and says, "paying for most of health care reform by raising taxes would be nothing less than cowardly and fiscally irresponsible." He continues, "the Congress is so desperate to find money and so unwilling to anger any powerful health care special interests we better get ready for some interesting rationalizations to promote tax increases in the place of fundamental reforms."After the hearing, ranking member Sen. Mike Enzi (R-Wyo.) gave a presentation at the Heritage Foundation on his preferences for bipartisan reform legislation and the Foundry"s Marguerite Higgins blogged Enzi"s key points. She says the senator wants to increase affordability, use private plans for coverage and ensure a bill is fully paid for.The White House appears to be initiating additional outreach efforts to mobilize support. Jose Antonio Vargas of the Washington Post"s Daily Dose reports that President Obama"s administration chose to send its first WhiteHouse.gov e-mail on health reform Wednesday. Vargas says, "It"s only fitting that Obama"s first official e-mail from the White House is about health care reform. As early as December, the incoming Obama administration began using new media tools to build grassroots support around the issue."Interesting elsewhere:
Health Insurance

Hearing Improved In First Successful Medical Treatment For Tumor-Inducing Genetic Disorder

Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). In a paper to appear in the July 23 New England Journal of Medicine, which is receiving early online release, researchers from Massachusetts General Hospital (MGH) report that bevacizumab treatment successfully shrank characteristic tumors in a small group of NF2 patients, the first reported successful NF2 treatment not involving surgery or radiation. "This kind of treatment response is unprecedented," says Scott Plotkin, MD, PhD, of the Pappas Center for Neuro-Oncology in the MGH Cancer Center, lead author of the NEJM paper. "Our study is the first to provide evidence that a drug can shrink vestibular schwannomas - benign tumors on the balance and hearing nerves - and the first to show that patients" hearing can be improved." NF2 is an inherited genetic disorder in which benign tumors develop throughout the nervous system. Vestibular schwannomas are the most common NF2-associated tumors, and although they grow slowly, they usually cause patients to lose all or most of their hearing by young adulthood or middle age. The tumors can be removed surgically or treated with radiation, but in patients with vestibular schwannomas on both sides, which is typical in NF2, such treatment usually leads to complete hearing loss. Growing vestibular schwannomas can also press on the brainstem, leading to headaches, difficulty swallowing and other serious neurologic symptoms. Since vestibular schwannomas are benign tumors, it was believed that they did not stimulate formation of new blood vessels as malignant tumors do. However, when the researchers studied tissue samples from NF2-related schwannomas, sporadic tumors not caused by NF2 and normal spinal nerves, they found evidence of excess blood vessel development and increased expression of angiogenesis-related molecules in both NF2-associated and sporadic vestibular schwannomas. With this suggestion that angiogenesis was involved in these tumors, members of the research team offered treatment with bevacizumab (Avastin), which is FDA-approved for treatment of several forms of cancer, to NF2 patients in danger of complete hearing loss or other significant neurological damage. Among the first ten NF2 patients to receive bevacizumab, treatment led to tumor shrinkage in nine, and six had 20 percent or greater reduction in tumor size. In those six patients, tumor shrinkage lasted from 11 to 16 months, longer than the four months typically seen in bevacizumab treatment of malignant brain tumors. Of seven patients who had started to lose their hearing before treatment, four experienced some hearing restoration - two returning to work or school as a result - improvement that has also lasted for up to 16 months. In one patient without significant tumor shrinkage or hearing improvement (he had lost all hearing prior to treatment), treatment alleviated headaches and nausea caused by brainstem compression, allowing him also to return to school. "This study has opened a new approach to research and understanding of these tumors," says Emmanuelle di Tomaso, PhD, the study"s senior author, formerly with the Steele Laboratory of Tumor Biology in the MGH Department of Radiation Oncology. "There had been a dogma that these tumors do not produce edema and are not angiogenic, concepts that now need to be reevaluated." She adds that the study also suggests that VEGF - the angiogenesis factor blocked by bevacizumab - may have a role in nerve physiology beyond the stimulation of blood vessel growth. Plotkin notes, "Based on the results of this study, we have just opened the first formal clinical trial of a drug treatment for NF2. We are testing an exciting new, oral VEGF inhibitor that will be easier for patients to take - bevacizumab is administered intravenously - and may have fewer side effects." Notes: Plotkin is an assistant professor of Neurology at Harvard Medical School (HMS). Formerly an assistant professor of Radiation Oncology at HMS, di Tomaso recently joined the Novartis Institutes for BioMedical Research. Additional co-authors of the NEJM report are Anat Stemmer-Rachamimov, MD, MGH Pathology; Fred Barker, MD, MGH Neurosurgery; Timothy Padera, PhD, Alex Tyrrell, PhD, and Rakesh Jain, PhD, MGH Radiation Oncology; Gregory Sorensen, MD, MGH Radiology, and Chris Halpin, PhD, Massachusetts Eye and Ear Infirmary. The study was supported by the HMS Center for Neurofibromatosis and Allied Disorders, Neurofibromatosis Inc. New England, Children"s Tumor Foundation, the Department of Defense, the National Institutes of Health, and the MGH Executive Committee on Research. No support was provided by Genentech, which produces and markets bevacizumab under the brand name Avastin. Katie Marquedant Massachusetts General Hospital


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):